Guggenheim Capital LLC Trims Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Guggenheim Capital LLC trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 76.0% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,743 shares of the medical equipment provider's stock after selling 21,357 shares during the quarter. Guggenheim Capital LLC's holdings in Hologic were worth $486,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Benson Investment Management Company Inc. acquired a new stake in shares of Hologic during the fourth quarter worth about $4,832,000. Principal Financial Group Inc. boosted its holdings in Hologic by 0.6% in the fourth quarter. Principal Financial Group Inc. now owns 271,152 shares of the medical equipment provider's stock valued at $19,547,000 after purchasing an additional 1,606 shares during the last quarter. Clean Yield Group grew its position in Hologic by 18.9% during the 4th quarter. Clean Yield Group now owns 45,646 shares of the medical equipment provider's stock worth $3,291,000 after purchasing an additional 7,266 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider's stock worth $110,700,000 after buying an additional 238,222 shares during the last quarter. Finally, Nordea Investment Management AB boosted its position in Hologic by 32.7% in the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock worth $159,911,000 after purchasing an additional 544,889 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Trading Down 8.0 %

Hologic stock traded down $4.56 during trading on Friday, reaching $52.72. 3,050,703 shares of the company were exchanged, compared to its average volume of 1,986,604. The stock's 50 day simple moving average is $60.50 and its two-hundred day simple moving average is $69.45. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The company has a market capitalization of $11.83 billion, a P/E ratio of 16.58, a PEG ratio of 2.14 and a beta of 0.54. Hologic, Inc. has a 52-week low of $52.14 and a 52-week high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Hologic's quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.03 earnings per share. On average, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on HOLX. Argus lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Monday, March 3rd. Citigroup dropped their target price on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $80.00 to $75.00 in a research note on Thursday, February 6th. Finally, William Blair reissued an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $83.77.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.